Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 16/20 | 0.64 |
| ▸ | CYP11B1 | P15538 | 15/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922179 | 0.85 | CCNC (0.50) | CYP11B2CYP11B1SLC22A12CYP17A1CYP19A1 | |
| SCHEMBL6919942 | 0.79 | CYP11B2 (0.66) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31061531 | 0.77 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6919823 | 0.76 | CYP11B1 (0.57) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1769970 | 0.76 | RPS6KA3 (0.46) | CYP11B2CYP11B1 | |
| SCHEMBL1769849 | 0.74 | SLC22A12 (0.56) | CYP11B2CYP11B1SLC22A12 | |
| SCHEMBL225893 | 0.74 | CYP11B2 (0.78) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1769848 | 0.74 | SLC22A12 (0.49) | CYP11B2CYP3A4CYP2D6SLC22A12 | |
| SCHEMBL1769990 | 0.74 | RPS6KA3 (0.42) | CYP11B2CYP11B1SLC22A12 | |
| SCHEMBL14225109 | 0.72 | RPS6KA3 (0.52) | CYP11B2CYP11B1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | claimed |
| EP-2993169-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| EP-2501678-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011061168-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011061168-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B2 4/4885CYP11B1 2/4885CYP1A2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.